23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.
- A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.
- 23andMe has more than 13 million genotyped customers, over 80% of whom consent to participate in research.
- 23andMe scientists study the aggregate, de-identified genetics of these participants, alongside more than 4 billion self-reported health data points.
- Title: A Phase 1 Dose Escalation and Expansion Study of the anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid Malignancies.